03:00 Wed 27 May 2020
Physiomics PLC - Fundraise
("
Fundraise
In the last few years, the Company has made significant progress, including:
• 70% compounded annual growth in total income FY 2017- 2019, culminating in its highest ever total income in FY 2019 of
• >
• Significant new clients
• Completion of a second Innovate
• Award of NIHR i4i grant (
• Entering into discussions with companies with an established presence in the field of personalised medicine with a view to exploring how its technology could be commercialised
On
In this regard, in the last two working days, the Company has received a strong indication that a significant contract is likely to be signed with a new large pharmaceutical client, with which it has been in discussions since late 2019. While is it still possible that the potential new client could withdraw, it is the Directors' opinion that this is unlikely. Should the contract be signed, the work is expected to take two of our technical staff around five months to complete.
In order to further develop its business, the Company is raising funds through the Fundraise to enable it to carry out activities including increasing its sales & marketing spend, recruiting a further member of its technical team and further investing in its personalised medicine technology as well as for general working capital purposes.
Director Participation in the Fundraise
Dr
Admission and total voting rights
Application will be made for the new Ordinary Shares to be admitted to trading on AIM and dealing is expected to commence on
For the purposes of the
Dr
Our team is committed to continuing to support global pharma and biotech companies in their drug discovery and development endeavours, and these funds will be mainly focused on growing our already strong pipeline of new business opportunities. I look forward to continuing to update shareholders on our progress."
The information contained within this announcement is deemed to constitute inside information as stipulated under the Market Abuse Regulations (EU) No. 596/2014.
Enquiries:
Dr
+44 (0)1865 784 980
Strand
+44 (0)20 7409 3494
+44 (0)20 3764 2341
Notes to Editor
About
Physiomics® is an oncology consultancy using mathematical models and its Virtual Tumour™ technology to support the development of cancer treatment regimens and personalised medicine solutions. The predictive capability of Virtual Tumour has been confirmed by 55 projects, involving over 25 targets and 60 drugs, and has worked with clients such as Merck KGaA, Merck & Co, Bayer and Lilly.
Based in
For more information please visit:
www.linkedin.com/company/physiomics-plc/
PDMR/PCA FCA Transaction Notification
1. |
Details of the person discharging managerial responsibilities / person closely associated |
|||||
a) |
|
Dr |
||||
2. |
Reason for the Notification |
|||||
a) |
Position/status |
Chief Executive Officer |
||||
b) |
Initial notification/amendment |
Initial notification |
||||
3. |
Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor |
|||||
a) |
|
|
||||
b) |
LEI |
213800A71DSZ6ABMTQ91 |
||||
4. |
Details of the transaction(s):section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv)each place where transactions have been conducted |
|||||
a) |
Description of the Financial instrument, type of instrument |
Ordinary shares of 0.4p each in the share capital of the |
||||
Identification code |
ISIN: GB00BDR6W943 |
|||||
b) |
Nature of the Transaction |
Issue of Ordinary shares |
||||
c) |
Price(s) and volume(s) |
|
||||
d) |
Aggregated information Aggregated volume Price |
N/A - single issuance |
||||
e) |
Date of the transaction |
|
||||
f) |
Place of the transaction |
|
1. |
Details of the person discharging managerial responsibilities / person closely associated |
|||||
a) |
|
Dr |
||||
2. |
Reason for the Notification |
|||||
a) |
Position/status |
Non-executive Chairman |
||||
b) |
Initial notification/amendment |
Initial notification |
||||
3. |
Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor |
|||||
a) |
|
|
||||
b) |
LEI |
213800A71DSZ6ABMTQ91 |
||||
4. |
Details of the transaction(s):section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv)each place where transactions have been conducted |
|||||
a) |
Description of the Financial instrument, type of instrument |
Ordinary shares of 0.4p each in the share capital of the |
||||
Identification code |
ISIN: GB00BDR6W943 |
|||||
b) |
Nature of the Transaction |
Issue of Ordinary shares |
||||
c) |
Price(s) and volume(s) |
|
||||
d) |
Aggregated information Aggregated volume Price |
N/A - single issuance |
||||
e) |
Date of the transaction |
|
||||
f) |
Place of the transaction |
|
1. |
Details of the person discharging managerial responsibilities / person closely associated |
|||||
a) |
|
Dr Christophe Chassagnole |
||||
2. |
Reason for the Notification |
|||||
a) |
Position/status |
Chief Operating Officer |
||||
b) |
Initial notification/amendment |
Initial notification |
||||
3. |
Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor |
|||||
a) |
|
|
||||
b) |
LEI |
213800A71DSZ6ABMTQ91 |
||||
4. |
Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv)each place where transactions have been conducted |
|||||
a) |
Description of the Financial instrument, type of instrument |
Ordinary shares of 0.4p each in the share capital of the |
||||
Identification code |
ISIN: GB00BDR6W943 |
|||||
b) |
Nature of the Transaction |
Issue of Ordinary shares |
||||
c) |
Price(s) and volume(s) |
|
||||
d) |
Aggregated information Aggregated volume Price |
N/A - single issuance |
||||
e) |
Date of the transaction |
|
||||
f) |
Place of the transaction |
|
This information is provided by RNS, the news service of the
The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of...
FOR OUR FULL DISCLAIMER CLICK HERE